UroGen Pharma Q1 2025: $100M Assets, $8.8M Net Loss

TL;DR

UroGen Pharma Q1 2025: $100M assets, $46.1M liabilities, $8.8M loss. Revenue $0.8M.

AI Summary

UroGen Pharma Ltd. filed its Q1 2025 10-Q report on May 12, 2025, for the period ending March 31, 2025. The company reported total assets of $100 million and total liabilities of $46.1 million, resulting in total equity of $42.2 million. Revenue for the quarter was $0.8 million, with a net loss of $8.8 million.

Why It Matters

This filing provides a snapshot of UroGen Pharma's financial health and operational performance for the first quarter of 2025, crucial for investors assessing the company's stability and growth prospects.

Risk Assessment

Risk Level: medium — The company reported a net loss, indicating ongoing operational costs exceeding revenue, which can pose a risk to financial stability if not managed effectively.

Key Numbers

• $100.0B — Total Assets (Represents the company's total resources as of March 31, 2025.)
• $46.1B — Total Liabilities (Indicates the company's total obligations as of March 31, 2025.)
• $42.2B — Total Equity (Shows the net worth of the company after deducting liabilities from assets.)
• $0.8M — Revenue (Represents the income generated from the company's operations in Q1 2025.)
• $8.8M — Net Loss (Indicates the company's profitability, showing a loss of $8.8 million for the quarter.)

Key Players & Entities

• UroGen Pharma Ltd. (company) — Filer of the 10-Q report
• 20250331 (date) — End of the reporting period
• 20250512 (date) — Filing date of the report
• $100,000,000 (dollar_amount) — Total assets
• $46,101,785 (dollar_amount) — Total liabilities
• $42,231,746 (dollar_amount) — Total equity
• $806,222 (dollar_amount) — Revenue for the period
• $8,803,000 (dollar_amount) — Net loss for the period

FAQ

From the Filing

0001437749-25-015956.txt : 20250512 0001437749-25-015956.hdr.sgml : 20250512 20250512080637 ACCESSION NUMBER: 0001437749-25-015956 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 98 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250512 DATE AS OF CHANGE: 20250512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UroGen Pharma Ltd. CENTRAL INDEX KEY: 0001668243 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38079 FILM NUMBER: 25932693 BUSINESS ADDRESS: STREET 1: 9 HA'TA'ASIYA ST CITY: RA'ANANA STATE: L3 ZIP: 4365007 BUSINESS PHONE: 972 9 770 7601 MAIL ADDRESS: STREET 1: 9 HA'TA'ASIYA ST CITY: RA'ANANA STATE: L3 ZIP: 4365007 10-Q 1 urgn20250331_10q.htm FORM 10-Q urgn20250331_10q.htm 0001668243 UroGen Pharma Ltd. false --12-31 Q1 2025 0.01 0.01 100,000,000 100,000,000 46,101,785 46,101,785 42,231,746 42,231,746 797,248 806,222 56 8,803 1 29 43,843 43,843 89 614,035 679,348 65,212 1 1 — 3 0 http://www.urogen.com/20250331#RightofuseAssetsOperatingAndFinanceLeases http://www.urogen.com/20250331#RightofuseAssetsOperatingAndFinanceLeases http://www.urogen.com/20250331#RightofuseAssetsOperatingAndFinanceLeases http://www.urogen.com/20250331#RightofuseAssetsOperatingAndFinanceLeases http://www.urogen.com/20250331#LeaseLiabilitiesNoncurrent http://www.urogen.com/20250331#LeaseLiabilitiesNoncurrent http://www.urogen.com/20250331#LeaseLiabilitiesNoncurrent http://www.urogen.com/20250331#LeaseLiabilitiesNoncurrent http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent 0 2 85 80 100.0 46.1 42.2 3 2 false false false false Other expenses primarily consist of insurance, sponsorship, grants, other fees and taxes. $0.2 million of raw materials are included within other non-current assets on the condensed consolidated balance sheets at December 31, 2024 These raw materials are not expected to be manufactured and sold within the next 12 months. Changes in non-current inventories are reflected on the condensed consolidated statements of cash flows within the caption of other non-current assets. No raw materials were included as non-current assets on the condensed consolidated balance sheets at March 31, 2025. The loss per share, both basic and diluted, for the first quarter of 2024 was revised to record an immaterial correction to the amounts originally reported in the March 31, 2024 Form 10-Q filed on May 13, 2024 by incorporating the 3,679,400 shares of pre-funded warrants outstanding as of the reporting period, which were not included in the previous calculations and are now reflected in the weighted average shares outstanding. $3.3 million and $3.0 million of the Amounts paid and payable are included as current portion of the prepaid forward obligation within other current liabilities on the condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023, respectively. 0001668243 2025-01-01 2025-03-31 xbrli:shares 0001668243 2025-05-05 thunderdome:item iso4217:USD 0001668243 2025-03-31 0001668243 2024-12-31 iso4217:ILS xbrli:shares 0001668243 2024-01-01 2024-03-31 iso4217:USD xbrli:shares 0001668243 us-gaap:CommonStockMember 2024-12-31 0001668243 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001668243 us-gaap:RetainedEarningsAppropriatedMember 2024-12-31 0001668243 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001668243 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001668243 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001668243 us-gaap:RetainedEarningsAppropriatedMember 2025-01-01 2025-03-31 0001668243 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001668243 us-gaap:CommonStockMember 2025-03-31 00